Role of Bai1 and Elmo Proteins in Apoptotic Cell Clearance
Bai1 和 Elmo 蛋白在凋亡细胞清除中的作用
基本信息
- 批准号:8896807
- 负责人:
- 金额:$ 31.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-05-01 至 2016-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAnti-Inflammatory AgentsAnti-inflammatoryApoptosisApoptoticAtherosclerosisAutoimmune DiseasesAutoimmunityAwardBAI1 geneBindingBiologyBrainCaenorhabditis elegansCell DeathCellsCellular biologyChronicComplexDefectDendritic CellsDevelopmentDiseaseEatingExcisionFailureFigs - dietaryFundingGenetic TranscriptionGenetic studyGerm CellsGoalsGuanine Nucleotide Exchange FactorsGuanosine Triphosphate PhosphohydrolasesHomeostasisHomologous GeneHumanInflammationInflammatoryInflammatory ResponseInterleukin-10Knock-outKnockout MiceKnowledgeLaboratoriesLeadLinkMammalian CellMediatingMediator of activation proteinMembrane ProteinsMusNational Institute of General Medical SciencesNatureNecrosisPathway interactionsPhagocytesPhagocytosisPhosphatidylserinesPhysiologyPlayProcessProductionProteinsRoleSecondary toSignal PathwaySignal TransductionSystemic Lupus ErythematosusTestingTestisTherapeutic InterventionThymus GlandTissuesTransgenic MiceTransgenic OrganismsTranslatingUp-RegulationWorkadapter proteinairway inflammationbasecell typechemotherapycytokinegenome wide association studyhuman diseasein vivoinsightmacrophagemembermouse modelmutantneurogenesisnoveloverexpressionreceptortumor
项目摘要
DESCRIPTION (provided by applicant): We turnover billions of cells in the body each day as part of normal homeostasis, and many of these cells die by the process of apoptosis. The apoptotic cells are quickly cleared by phagocytes in vivo, in an 'immunologically silent' fashion. Defects in prompt removal leads to secondary necrosis, with the release of intracellular contents from the dying cells promoting chronic tissue inflammation, which has been linked to autoimmune disorders such as SLE, airway inflammation, and atherosclerosis. Thus, a better knowledge of the mechanisms of apoptotic cell recognition and clearance becomes necessary for countering these disorders. This current competitive renewal application is based on the progress made during the two previous funding periods of 4 years each. We first identified a novel cytoplasmic engulfment adapter protein ELMO1, and defined the ELMO/Dock180/Rac signaling pathway as an evolutionarily conserved module for promoting apoptotic cell engulfment. We then identified the membrane protein BAI1 as the engulfment receptor upstream of ELMO1; independently, we generated knockout mice for Elmo1 to identify its requirement in apoptotic germ cell clearance in the testes, and during neurogenesis in the brain. These works have also raised a number of exciting next set of questions on signaling via the BAI1/ELMO1 module in vivo, and how this pathway may dampen inflammation in tissues. In Aim1 of this proposal, using mice recently generated in our laboratory where the Bai1 locus has been targeted for deletion (floxed as well as straight knockout), we will test the hypothesis that BAI1 plays a role in apoptotic cell clearance in vivo in two different tissues, the thymus and the testes. Moreover, using inducible transgenic mice that overexpress wild type or a mutant form of BAI1, we will test whether BAI1 provides unique versus redundant signals in promoting engulfment in vivo. Aim 2 focuses on how apoptotic cell recognition translates to anti-inflammatory cytokine production, key feature of apoptotic cell clearance that is not fully understood. We will test the hypothesis that the BAI1-ELMO1-mediated signaling contributes to anti-inflammatory responses of phagocytes. Specifically, we will test how an unexpected interaction between ELMO1 and components of the transcriptional machinery (which we have discovered in our preliminary studies), contribute to the anti-inflammatory gene transcription during engulfment. We will extend these in vivo using mice deficient in Elmo2 (that we have recently generated) in a mouse model of tissue inflammation. Collectively, we expect these studies to provide exciting new information on signaling via the BAI1/Elmo1 signaling pathway in cell clearance in vivo. Since altered expression of ELMO1 and BAI1 are genetically linked to inflammatory disorders in humans, the results from the proposed studies could be relevant for therapeutic intervention in inflammatory disorders.
描述(由申请者提供):我们每天在体内更新数十亿个细胞,作为正常内稳态的一部分,其中许多细胞在凋亡过程中死亡。体内的吞噬细胞以一种“免疫沉默”的方式迅速清除了凋亡细胞。迅速去除的缺陷会导致继发性坏死,死亡细胞释放细胞内内容物促进慢性组织炎症,这与自身免疫性疾病有关,如系统性红斑狼疮、呼吸道炎症和动脉粥样硬化。因此,更好地了解凋亡细胞识别和清除的机制对于对抗这些疾病是必要的。目前的竞争性续签申请是根据前两个供资期间取得的进展提出的,每个供资期限为4年。我们首先鉴定了一种新的细胞质吞噬适配蛋白ELMO1,并将Elmo/Dock180/Rac信号通路定义为促进细胞凋亡吞噬的进化保守模块。然后,我们确定膜蛋白BAI1是ELMO1上游的吞噬受体;独立地,我们为ELMO1产生了敲除小鼠,以确定它在睾丸中的凋亡生殖细胞清除和大脑中的神经发生过程中的需求。这些工作还提出了一些令人兴奋的下一组问题,涉及体内通过BAI1/ELMO1模块的信号传递,以及这一途径如何抑制组织中的炎症。在这项建议的Aim1中,使用我们实验室最近产生的BAI1基因被靶向缺失(花蕾和直接敲除)的小鼠,我们将测试BAI1在体内两个不同组织--胸腺和睾丸--的凋亡细胞清除中发挥作用的假设。此外,使用过度表达野生型或突变形式的BAI1的可诱导转基因小鼠,我们将测试BAI1在促进体内吞噬方面是否提供独特的与冗余的信号。目的2重点研究细胞凋亡识别如何转化为抗炎细胞因子的产生,这是细胞凋亡清除的关键特征,目前还不完全清楚。我们将验证BAI1-ELMO1介导的信号有助于吞噬细胞抗炎反应的假设。具体地说,我们将测试ELMO1和转录机制组件(我们在初步研究中发现)之间的意外相互作用如何有助于吞噬过程中的抗炎基因转录。我们将在体内使用Elmo2缺陷的小鼠(我们最近培育的)在组织炎症的小鼠模型中推广这些方法。总而言之,我们期望这些研究能在体内细胞清除中通过BAI1/ELMO1信号通路提供令人兴奋的新信息。由于ELMO1和BAI1的表达改变与人类的炎症性疾病有遗传联系,因此拟议的研究结果可能与炎症性疾病的治疗干预相关。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ulrike Lorenz其他文献
Ulrike Lorenz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ulrike Lorenz', 18)}}的其他基金
A New Approach to Modulating CAR T Cell Activity
调节 CAR T 细胞活性的新方法
- 批准号:
10709301 - 财政年份:2022
- 资助金额:
$ 31.96万 - 项目类别:
A New Approach to Modulating CAR T Cell Activity
调节 CAR T 细胞活性的新方法
- 批准号:
10365202 - 财政年份:2022
- 资助金额:
$ 31.96万 - 项目类别:
Role of SHP-1 in T cell activation and development
SHP-1 在 T 细胞激活和发育中的作用
- 批准号:
7922994 - 财政年份:2009
- 资助金额:
$ 31.96万 - 项目类别:
Role of Bai1 and Elmo Proteins in Apoptotic Cell Clearance
Bai1 和 Elmo 蛋白在凋亡细胞清除中的作用
- 批准号:
8599030 - 财政年份:2003
- 资助金额:
$ 31.96万 - 项目类别:
Role of Bai1 and Elmo Proteins in Apoptotic Cell Clearance
Bai1 和 Elmo 蛋白在凋亡细胞清除中的作用
- 批准号:
8707468 - 财政年份:2003
- 资助金额:
$ 31.96万 - 项目类别:
Role of SHP-1 in T cell activation and development
SHP-1 在 T 细胞激活和发育中的作用
- 批准号:
6749457 - 财政年份:2001
- 资助金额:
$ 31.96万 - 项目类别:
Role of SHP-1 in T cell activation and development
SHP-1 在 T 细胞激活和发育中的作用
- 批准号:
7637435 - 财政年份:2001
- 资助金额:
$ 31.96万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 31.96万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 31.96万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 31.96万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 31.96万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 31.96万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 31.96万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 31.96万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 31.96万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 31.96万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 31.96万 - 项目类别:














{{item.name}}会员




